Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
EMD Serono
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
BTG plc Close Period Update
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Drug Safety Labeling Changes
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
UCSF Neuroimmunology Seminar
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Impact of MS during the critical window of brain development.

Pages